Compare Gilead Sciences, Inc. (GILD) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Monster Beverage Corp — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Monster Beverage Corp trades at $99.75 (market cap $95.42B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| GILD | MNST | |
|---|---|---|
Market Cap | $163.51B | $95.42B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $98.01 |
52-Week Low | $108.22 | $58.65 |
Enterprise Value | $178.05B | $93.72B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Monster Beverage (MNST) trades at $98.005, up 0.96% on the day, with a bullish technical signal and strong fundamental performance. The company has consistently beaten earnings expectations for the last three quarters, with Q1 2026 EPS of $0.58 beating estimates of $0.527. Revenue growth is robust, increasing from $6.3B in 2022 to $8.3B in 2025, while net profit margins have expanded to 23.11%. A 2-for-1 stock split was recently announced, effective August 11, 2026.
The outlook remains positive driven by international expansion and product innovation, with 45% of sales now from overseas. Key risks include premium valuation multiples (P/E of 47.14) and competitive pressure in the energy drink sector. Analyst consensus is 'Buy' with a $94.60 price target, though the current price trades slightly above this target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
